Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report

Breast

Volumn 19, Issue 1, 2010, Pages 33-37

  Munzone, E ^a   Di Pietro, A ^a   Goldhirsch, A ^a   Minchella, I ^a   Verri, E ^a   Cossu Rocca, M ^a   Marenghi, C ^a   Curigliano, G ^a   Radice, D ^a   Adamoli, L ^a   Nole F ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Advanced breast cancer; Metronomic chemotherapy; Pegylated liposomal doxorubicin

Indexed keywords

ALIZAPRIDE; ANTHRACYCLINE; CHLORPHENIRAMINE; DEXAMETHASONE; DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PILOT STUDY; TIME; WOMEN'S HEALTH;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; TIME FACTORS; WOMEN'S HEALTH;

EID: 77951885289     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.10.003     Document Type: Article

References (28)

1. Mayer E., Burstein H.J. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007 Apr, 21(2):257-272.
2. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
3. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60(7):1878-1886.
4. Bocci G., Nicolaou K.C., Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002, 62:6938-6943.
5. Miller K., Sweeney C., Sledge G. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195-1206.
6. Orlando L., Cardillo A., Rocca A., et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006 Sep, 17(8):961-967.
7. Orlando L., Cardillo A., Ghisini R., et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006 Sep 15, 6:225.
8. Dellapasqua S., Bertolini F., Bagnardi V., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008 Oct 20, 26(30):4899-4905.
9. O'Brien M.E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008 Jan, 19(1):1-7.
10. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002, 4(3):95-99.
11. Northfelt D.W., Martin F.J., Working P., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol 1996 Jan, 36(1):55-63.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2, 92(3):205-216.
13. Berry G., Billingham M., Alderman E., et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998 Jul, 9(7):711-716.
14. Goebel F.D., Goldstein D., Goos M., et al. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer 1996 Apr, 73(8):989-994.
15. Northfelt D.W., Dezube B.J., Thommes J.A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998 Jul, 16(7):2445-2451.
16. Cooley T., Henry D., Tonda M., et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 2007 Jan, 12(1):114-123.
17. Sehouli J., Oskay-Ozcelik G., Kühne J., Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 2006 Jun, 17(6):957-961.
18. Tas F., Guney N., Derin D., Aydiner A., Topuz E. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Int J Clin Oncol 2008 Apr, 13(2):156-160.
19. Strauss H.G., Hemsen A., Karbe I., et al. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs 2008 Jun, 19(5):541-545.
20. Charrois G.R.J., Allen T.M. Multiple injections of Pegylated Liposomal Doxorubicin: pharmacokinetics and therapeutic activity. JPET 2003, 306:1058-1067.
21. Ranson M.R., Carmichael J., O'Byrne K., et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997 Oct, 15(10):3185-3191.
22. Lyass O., Uziely B., Ben-Yosef R., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000 Sep 1, 89(5):1037-1047.
23. Al-Batran S.E., Bischoff J., von Minckwitz G., et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006 Jun 5, 94(11):1615-1620.
24. Al-Batran S.E., Meerpohl H.G., von Minckwitz G., et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006, 70(2):141-146.
25. Rivera E., Valero V., Esteva F.J., et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 2002 Apr, 49(4):299-302.
26. Keller A.M., Mennel R.G., Georgoulias V.A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004 Oct 1, 22(19):3893-3901.
27. Alba E., Ruiz-Borrego M., Martín M., et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 1007.
28. Verma S., Dent S., Chow B.J., Rayson D., Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008 Aug, 34(5):391-406.